The epidermal growth factor family has a dual role in deciding the fate of cancer cells

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 7, 2006, Pages 623-630

  Memon, Ashfaque A ^a   Sorensen, B Sandahl ^a   Nexo, E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Apoptosis; EGF; ErbB; Heregulin; HRG; Neuregulin; Proliferation

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GEFITINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; NEU DIFFERENTIATION FACTOR 1 ALPHA; NEU DIFFERENTIATION FACTOR 1 BETA; NEU DIFFERENTIATION FACTOR 2 ALPHA; NEU DIFFERENTIATION FACTOR 2 BETA; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL FATE; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REAL TIME POLYMERASE CHAIN REACTION;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MULTIGENE FAMILY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 33751094310     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510600891458     Document Type: Conference Paper

References (41)

1. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL. Insect cell-expressed P180(Erbb3) possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci 1994;91:8132-6.
2. Burden S, Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 1997;18:847-55.
3. Ivanov VN, Hei TK. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene 2005;24:616-26.
4. Jorissen RN, Walker F, Pouliot N, Garrett TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
5. Gullick WJ. The type 1 growth factor receptors and their ligands considered as a complex system. Endocrine-Related Cancer 2001;8:75-82.
6. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature Rev Mol Cell Biol 2001;2:127-37.
7. Massague J, Pandiella A. Membrane-anchored growth factors. Annu Rev Biochem 1993;62:515-41.
8. Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003;10:234-41.
9. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
10. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 2004;6:R246-51.
11. Memon AA, Sorensen BS, Melgard P, Fokdal L, Thykjaer T, Nexo E. Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients. Br J Cancer 2004;91:2034-41.
12. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005;11:2163-8.
13. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001;21:4265-75.
14. Chomczynski P, Sacchi N. Single-step method of Rna isolation by acid guanidinium thiocyanate phenol chloroform extraction. Anal Biochem 1987;162:156-9.
15. Schooler K, Wiley HS. Ratiometric assay of epidermal growth factor receptor tyrosine kinase activation. Anal Biochem 2000;277:135-42.
16. Kristensen JK, Lose G, Lund F, Nexo E. Epidermal growth-factor in urine from patients with urinary-bladder tumors. Eur Urol 1988;14:313-14.
17. Mellon JK, Cook S, Chambers P, Neal DE. Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. Br J Cancer 1996;73:654-8.
18. Ravery V, Grignon D, Angulo J, Pontes E, Montie J, Crissman J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 1997;25:9-17.
19. Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson MA. Invasion of the bladder by transitional cell carcinoma - Its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998;82:715-23.
20. Lonn U, Lonn S, Friberg S, Nilsson B, Silfversward C, Stenkvist B. Prognostic value of amplification of cerb-B2 in bladder carcinoma. Clin Cancer Res 1995;1:1189-94.
21. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:5670-6.
22. Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 2004;10:4083-8.
23. Popov Z, Gil-Diez-De-Medina S, Ravery V, Hoznek A, Bastuji-Garin S, Lefrere-Belda MA, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004;22:93-101.
24. Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005;304:604-19.
25. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004;91:1532-42.
26. Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 2005;11:2163-8.
27. Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001;21:4265-75.
28. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003;30:3-11.
29. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000;20:91-5.
30. Banerjee S, Sengupta K, Saxena NK, Dhar K, Banerjee SK. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res 2005;3:151-62.
31. Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook P, Ramsey GW, et al. Auto- and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem 1994;269:22817-22.
32. Inui Y, Higashiyama S, Kawata S, Tamura S, Miyagawa JI, Taniguchi N, et al. Expression of heparin-binding epidermal growth-factor in human hepatocellular-carcinoma. Gastroenterology 1994;107:1799-804.
33. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994;202:1705-9.
34. Naef M, Yokoyama M, Friess H, Buchler MW, Korc M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996;66:315-21.
35. Tsai MS, Shamon-Taylor LA, Mehmi I, Tang CK, Lupu R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 2003;22:761-8.
36. Nakano N, Higashiyama S, Ohmoto H, Ishiguro H, Taniguchi N, Wada Y. The N-terminal region of NTAK/neuregulin-2 isoforms has an inhibitory activity on angiogenesis. J Biol Chem 2004;279:11465-70.
37. Penne K, Bohlin C, Schneider S, Allen D. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. Cancer Nurs 2005;28:481-6.
38. Ariyama H, Qin B, Baba E, Tanaka R, Mitsugi K, Harada M, et al. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 2006;97:724-34.
39. Hara F, Aoe M, Doihara H, Taira N, Shien T, Takahashi H, et al. Antitumor effect of gefitinib ("Iressa") on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett 2005;226:37-47.
40. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003;106:758-65.
41. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:4217-25.